Larimar Therapeutics, Inc.

NASDAQ:LRMR

Biotechnology

Healthcare
$3.23 +0.99%

+$0.04 today

Market cap
$337.45M
Beta
0.82
P/E (TTM)
-1.8
EPS (TTM)
-$1.95
52W Low $2.22High $6.42

Volume 1.41M

Average 1.73M

LRMR Other Non-current Assets

Long-term assets not reported separately.

Larimar Therapeutics, Inc.NASDAQ: LRMR

Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026

Other non-current assets falls 6.6% from a year ago

Other non-current assets stood at $1.11M at the end of Q1 FY2026, down 6.6% from a year earlier and down 1.7% from the prior quarter. Over 3 fiscal years it compounded at -17.0% a year.

Context

  • Other non-current assets amounted to 0.5% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
  • Other non-current assets increased in 1 of the last 3 fiscal years.

What to watch

Whether other non-current assets keeps falling in the next quarterly balance sheet after a -6.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.11M-1.7% QoQ
Last fiscal yearDec 2025
$1.13M-6.1% YoY
Year agoMar 2025
$1.19M-6.6% since
Other Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.6%——
1 year-6.1%——
3-year CAGR-17.0%——
5-year CAGR——
10-year CAGR——

Other Non-current Assets history

USD · from the balance sheet

Latest · FY2025
1.13M USD
Year-over-year change
-6.1%
4-year CAGR
+14.0%

Other Non-current Assets vs competitors

How LRMR compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -6.6% is the 7th highest of 10, against a peer median of +10.9%.
  • Other non-current assets amounts to 0.5% of total assets for LRMR, versus a peer median of 0.9%.
LRMR Competitors
Other Non-current Assets for LRMR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANNXAnnexon, Inc.Mar 2026$9.75M USD+54.0%+110.2%3.7%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026$6.64M USD+104.4%-24.3%2.7%
KYTXKyverna Therapeutics, Inc.Mar 2026$5.57M USD+32.5%+64.2%2.2%
DBVTDBV Technologies S.A.Mar 2026$5.5M USD+10.9%-3.8%2.1%
KRROKorro Bio, Inc.Mar 2026$2.35M USD-64.3%+5.8%1.3%
ENGNenGene Holdings Inc.Apr 2026$1.38M USD+0.0%+13.2%0.4%
LRMRLarimar Therapeutics, Inc.Mar 2026$1.11M USD-6.6%-17.0%0.5%
AMRNAmarin Corporation plcMar 2026$1.01M USD-98.3%-81.4%0.2%
ANROAlto Neuroscience, Inc.Mar 2026$838K USD+47.3%+83.2%0.3%
ALTAltimmune, Inc.Mar 2026$746K USD-53.9%+32.3%0.2%
ACIUAC Immune S.A.Mar 2026CHF 0 CHF——0.0%
Peer median (excluding LRMR) —+10.9%+13.2%0.9%

Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents70.1M26.83M26.75M33.22M85.41M
Short-term Investments091.6M60.04M150.24M51.44M
Net Receivables208K001.05M747K
Inventory00000
Other Current Assets279K238K709K517K253K
Total Current Assets72.2M120.74M90.18M195.3M142.02M
Property, Plant & Equipment (Net)4.46M3.69M3.76M3.72M2.69M
Goodwill00000
Intangible Assets00000
Long-term Investments1.34M01.34M00
Tax Assets00000
Other Non-current Assets669K1.98M659K1.2M1.13M
Total Non-current Assets6.46M5.67M5.76M4.92M3.82M
Total Assets78.67M126.41M95.94M200.23M145.84M
Account Payables1.66M1.69M1.28M2.42M5.22M
Short-term Debt00001.11M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities000054.69M
Total Current Liabilities8.85M10.71M9.51M24.36M64.8M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities5.41M4.8M4.71M4.06M2.96M
Total Liabilities14.25M15.5M14.22M28.41M67.76M
Common Stock18K43K43K64K83K
Retained Earnings(116.25M)(151.61M)(188.55M)(269.16M)(434.83M)
Accumulated OCI(0)(31K)81K148K54K
Other Stockholders Equity00000
Minority Interest00000
Total Equity64.41M110.9M81.72M171.81M78.09M
Total Debt6M5.41M5.55M5.12M4.07M
Net Debt(64.1M)(21.42M)(21.2M)(28.1M)(81.35M)

Larimar Therapeutics, Inc.

NASDAQ:LRMR

Intrinsic Alpha fair value

Locked

Current Price

$3.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.